Clinical Trials | December 30, 2025
Biohaven reports Phase 2 depression trial results
Despite some promising subgroup signals, the company indicated it will not pursue further psychiatric trials
Despite some promising subgroup signals, the company indicated it will not pursue further psychiatric trials
Lucid-MS represents a potential breakthrough in the treatment of multiple sclerosis
The approval follows results from the DESTINY-Breast06 phase 3 trial, which showed ENHERTU significantly extended progression-free survival compared to chemotherapy
Indian Pharmacopoeia is now recognised in 19 countries, reflecting growing international confidence in India’s regulatory and scientific capabilities
Nona aims to help global biopharmaceutical companies fast-track clinical trial initiation without compromising scientific rigor or quality standards
The collaboration aims to combine synthetic biology with cutting-edge detection technology to create a first-of-its-kind oral pill embedded with tumor-targeting sensors
Tolebrutinib had been provisionally approved in the United Arab Emirates in July 2025 for nrSPMS to slow disability accumulation independent of relapse activity
The multicenter study will enroll 75 patients across 16 sites in Germany, Bulgaria, Poland, and Spain
The new single-use commercial facility will be among India’s largest, featuring advanced technologies to produce high-quality biologics and specialty pharmaceuticals
Subscribe To Our Newsletter & Stay Updated
